[Cross-over comparison of the pharmacokinetics of estradiol during hormone replacement therapy with estradiol valerate or micronized estradiol].
OBJECTIVE
The aim of this randomized cross-over study was the comparison between a sequential 28-day hormone replacement therapy (HRT) using micronized estradiol and a cyclic 21-day HRT using estradiol valerate with regard to the pharmacokinetics of estradiol. -


METHODS
Fifty postmenopausal women were randomly assigned to be treated either with Trisequens(R) for 28 days or with Sisare(R) for 21 days. After a wash-out cycle, the women were treated for one cycle with the other preparation in a cross-over fashion. The pharmacokinetic profile of the serum concentrations of estradiol was measured on day 1, 21 and 28 each immediately before and 1, 2, 4, 6, 8, and 10 hours after intake of a tablet, and the AUC (area under the curve) was calculated. -


RESULTS
The serum concentrations of estradiol increased from a mean of 10 pg/ml up to 40 pg/ml (Trisequens(R)) and 30 pg/ml (Sisare(R)) on day 1, and to 80 pg/ml (Trisequens(R)) and 60 pg/ml (Sisare(R)) on day 21, and declined to 40 pg/ml (Trisequens(R)) and 10 pg/ml (Sisare(R)) on day 28. The AUC as calculated from both treatment cycles, was significantly higher on day 1, 21, and 28 during treatment with Trisequens(R) than with Sisare(R). This difference was, however, not signifcant on day 1 and 21 of the first treatment cycle. -


CONCLUSIONS
During treatment with 2 mg micronized estradiol the serum concentrations are significantly higher than with 2 mg estradiol valerate. On day 28 of treatment with Sisare(R), the estradiol levels decline to baseline values, while using Trisequens(R) they remain in the range of those measured on day 1.
Wiegratz
I
I
Zentrum der Frauenheilkunde und Geburtshilfe, Johann-Wolfgang-Goethe-Universität Frankfurt am Main.
Fink
T
T
Rohr
U D
UD
Lang
E
E
Leukel
P
P
Kuhl
H
H
D000368:Aged; D003279:Contraceptives, Oral, Sequential / Q000493:pharmacokinetics; D018592:Cross-Over Studies; D004338:Drug Combinations; D004958:Estradiol / Q000031:analogs & derivatives* / Q000097:blood / Q000493:pharmacokinetics*; D004964:Estriol / Q000493:pharmacokinetics; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000379:methods*; D005260:Female; D006801:Humans; D007118:Immunoassay / Q000379:methods; D008163:Luminescent Measurements; D008875:Middle Aged; D009640:Norethindrone / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D017698:Postmenopause
D003279:Contraceptives, Oral, Sequential; D004338:Drug Combinations; D004958:Estradiol; C032040:Trisequens; D004964:Estriol; D009640:Norethindrone